Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
NeuroSense Therapeutics Ltd. (NRSN) had Stock-Based Compensation of $0.31M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$1.56M |
|
$0.06M |
|
$0.13M |
|
$1.68M |
|
$2.20M |
|
-- |
|
-- |
|
$2.20M |
|
$-0.52M |
|
$-0.52M |
|
$-0.52M |
|
24.60M |
|
| Cash Flow Statement Financials | |
$-4.00M |
|
$-0.01M |
|
$1.30M |
|
$3.38M |
|
$0.67M |
|
$-2.71M |
|
|
Stock-Based Compensation |
$0.31M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|